Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Tropical Medicine Research Institute | OTHER |
| World Health Organization | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In areas of seasonal malaria transmission, treatment of carriers of malaria parasites, whose parasitaemia persists at very low levels throughout the dry season, could be a useful strategy for malaria control in areas with a short transmission season. We did a randomized trial to compare two regimens for clearance of low level parasitaemia in the dry season.
104 individuals with low density Plasmodium falciparum infection detected by polymerase chain reaction (PCR) were randomized to receive sulfadoxine-pyrimethamine and three daily doses of artesunate (SP+AS) or SP+AS and a dose of primaquine (SP+AS+PQ), and were followed up for 14 days during the transmission-free season in Eastern Sudan. Subjects were visited on days 3, 7 and 14 after the start of treatment to record any adverse events and to detect P.falciparum using PCR. PCR positive samples were tested for gametocytes using RT-PCR. Packed cell volume was measured on days 7 and 14.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Active Comparator | Sulfadoxine pyrimethamine plus three daily doses of artesunate |
|
| 2 | Experimental | Sulfadoxine pyrimethamine plus artesunate plus primaquine |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| sulfadoxine-pyrimethamine (SP) plus artesunate (AS) | Drug | sulfadoxine-pyrimethamine (SP) plus three daily doses of artesunate (AS) |
|
| Measure | Description | Time Frame |
|---|---|---|
| P.falciparum parasitaemia detected by PCR on days 3,7 and 14. | 14 days from start of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Presence of gametocytes detected by RT-PCR on days 3, 7 and 14. | 14 days from start of treatment | |
| Packed Cell volume on days 7 and 14. | Over 14 days from start of treatment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Badria B El Sayed, PhD | TMRI, Khartoum | Principal Investigator |
| Omer Z Baraka, MD | Faculty of Medicine, University of Khartoum | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tropical Medicine Research Institute | Khartoum | Sudan |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 18074034 | Derived | El-Sayed B, El-Zaki SE, Babiker H, Gadalla N, Ageep T, Mansour F, Baraka O, Milligan P, Babiker A. A randomized open-label trial of artesunate- sulfadoxine-pyrimethamine with or without primaquine for elimination of sub-microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan. PLoS One. 2007 Dec 12;2(12):e1311. doi: 10.1371/journal.pone.0001311. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| primaquine (PQ) plus SP+AS | Drug | single dose of primaquine on day 4 |
|
| ID | Term |
|---|---|
| D008288 | Malaria |
| ID | Term |
|---|---|
| D011528 | Protozoan Infections |
| D010272 | Parasitic Diseases |
| D007239 | Infections |
| D000096724 | Mosquito-Borne Diseases |
| D000079426 | Vector Borne Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C001205 | fanasil, pyrimethamine drug combination |
| D011319 | Primaquine |
| ID | Term |
|---|---|
| D000634 | Aminoquinolines |
| D011804 | Quinolines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided